Search results
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements
GuruFocus.com via Yahoo Finance· 4 hours agoThe biopharmaceutical company, known for its focus on developing treatments for serious and rare...
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings
GuruFocus.com via Yahoo Finance· 18 hours agoThe company, a prominent biopharmaceutical entity focused on innovative therapies for eye diseases,...
How AI Has Already Begun to Change These Workers’ Jobs
The Wall Street Journal· 2 hours agoArtificial intelligence hasn’t been the job killer that some predicted, at least not so far. Census...
Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst - Glaukos...
Benzinga· 6 days agoThursday, Glaukos Corporation GKOS reported a first-quarter adjusted EPS loss of $(0.70), up from...
Is Wegovy or Ozempic Better for Weight Loss?
MediaFeed via AOL· 5 days agoJacob Wackerhausen/Istockphoto The most common side effects of Ozempic include: Pancreatitis (inflammation of the pancreas) Diabetic retinopathy...
How to identify ultra-processed foods (UPFs) – and the surprising ones hiding in your cupboard
The Telegraph via Yahoo News· 5 hours agoIt’s now impossible to avoid warnings about the dangers of eating too much ultra-processed food...
Want to show teachers appreciation? A top Florida school gives them more freedom
WJHL· 2 days agoWaning job satisfaction over the last two decades has accompanied a decline in teachers’ sense of...
Q1 2024 Halozyme Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 5 hours agoWe're also pleased to report two pipeline advancements. Firstly, our Agennix initiated registrational studies of efgartigimod subcutaneous with Enhanze for a new indication thyroid ...
5 health behaviors that can make you blind
Rolling Out· 23 hours agoMost of us are aware that certain diseases or injuries can lead to vision loss but not realize that everyday behaviors can also harm our sight.
HanAll Biopharma initiates Phase III DED treatment trial
Clinical Trials Arena via Yahoo Finance· 2 days agoHanAll Biopharma has commenced the Phase III VELOS-4 trial for tanfanercept, a new topical...
